Despite regulatory uncertainty, healthcare M&A activity remains constant

More than 200 health services deals were reported in the second quarter of 2018, continuing the ongoing streak of mergers and acquisitions in the sector, according to PricewaterhouseCoopers.

Despite regulatory uncertainty in the healthcare environment, mega-deals marched forward during the quarter, which was the 14th consecutive quarter with more than 200 deals. 

Year over year, healthcare deals rose 9.4 percent in the second quarter of 2018. Compared to the first quarter of 2018, deals declined 7.3 percent, with 255, according to PwC’s US Health Services Deal Insights Q2 2018 report.

In addition, the total value of deals during the quarter declined from the prior quarter and a year ago, but the presence of mega-deals remained high. Deal value dropped 66.1 percent from the first quarter of the year and 50.7 percent from the second quarter of 2017. One deal exceeded $5 billion during the second quarter, on par with the average deal volume in the preceding seven quarters. 

Private equity firms played a major role in deals during the quarter, with more than four transactions priced above $500 million. These included KKR’s acquisition of Envision for $9.9 billion; the acquisition of Curo Health Services and Kindred Healthcare; the $2.5 billion sale of Sound Inpatient Physicians Holdings; and the simultaneous acquisition of Cord Blood Registry and California Cryobank.

The deals come amid policy uncertainties related to the Affordable Care Act and tax reform implications. These factors may actually be influencing more deals, and the trends of the first half of the year are likely to continue throughout 2018, according to PwC. 

“Quarterly health services deal volume continues to be robust, having exceeded 220 deals for the previous several years,” Thad Kresho, U.S. health services deals leader with PwC, said in the report. “Similar to Q1 2018, multiple factors are contributing to the deal activity, including both private equity fund raising/ investment and corporate strategic initiatives. We don't anticipate these trends to slow during the remainder of 2018.”

Other notable transactions during the quarter include Amazon’s acquisition of PillPack for an estimated $1 billion and Welltower’s joint venture with ProMedica to purchase Quality Care Properties. WellCare also announced its deal to acquire Meridian Health Plans for $2.5 billion.

Long-term care was the most active sub-sector in the healthcare M&A landscape during the second quarter, with 104 deals, or 40.8 percent of the deal volume. Managed care and home health care saw the highest growth in deal volumes, at 100 percent and 66.7 percent, respectively. 

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.